| abstract |
In some embodiments, the invention provides a pharmaceutical composition comprising a phosphoinositide 3-kinase (PI3K) inhibitor, including a PI3K inhibitor selective for both gamma- and delta-islet and selective for both gamma- and delta- Lt; RTI ID = 0.0 > (BTK) < / RTI > inhibitor. In some embodiments, the invention provides a method of treating a subject suffering from a disorder selected from the group consisting of macrophages, monocytes, mast cells, ancillary T cells, cytotoxic T cells, regulatory T cells, natural killer cells, And methods of treatment using BTK inhibitors and PI3K-delta inhibitors for the treatment of solid tumor cancers by modulating the tumor microenvironment, including fibroblasts. |